About Novavax
Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs. Additional information about Novavax is available at http://www.novavax.com and in the company's various filings with the Securities and Exchange Commission.
Forward-Looking Statements
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters,
including expectations regarding product sales, operating expenses, and
clinical developments are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act. Novavax cautions that these
forward-looking statements are subject to numerous assumptions, risks and
uncertainties, which change over time. Factors that may cause actual
results to differ materially from the results discussed in the
forward-looking statements or historical experience include risks and
uncertainties, including the failure by Novavax to secure and maintain
relationships with collaborators; risks relating to the early stage of
Novavax's product candidates under development; uncertainties relating to
clinical trials; risks relating to the commercialization,
'/>"/>
| SOURCE Novavax, Inc. Copyright©2007 PR Newswire. All rights reserved |